Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) announced a quarterly dividend on Tuesday, February 11th,Wall Street Journal reports. Shareholders of record on Friday, February 21st will be paid a dividend of 0.47 per share on Monday, March 31st. This represents a $1.88 annualized dividend and a yield of 13.42%. The ex-dividend date of this dividend is Friday, February 21st.
Abrdn Life Sciences Investors Stock Up 0.4 %
NYSE HQL traded up $0.05 on Friday, reaching $14.01. 99,663 shares of the company's stock traded hands, compared to its average volume of 121,445. Abrdn Life Sciences Investors has a 12 month low of $12.76 and a 12 month high of $15.90. The stock has a 50-day simple moving average of $13.74 and a 200 day simple moving average of $14.50.
Insider Buying and Selling
In related news, major shareholder Saba Capital Management, L.P. sold 36,536 shares of the stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $13.75, for a total transaction of $502,370.00. Following the completion of the sale, the insider now directly owns 3,276,181 shares in the company, valued at $45,047,488.75. This represents a 1.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 108,186 shares of company stock worth $1,508,866 in the last 90 days. 10.06% of the stock is owned by company insiders.
Abrdn Life Sciences Investors Company Profile
(
Get Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Featured Stories
Before you consider Abrdn Life Sciences Investors, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abrdn Life Sciences Investors wasn't on the list.
While Abrdn Life Sciences Investors currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
